Moderna, Inc. · NASDAQ:MRNA
Moderna — 40th Annual J.P. Morgan Healthcare Conference (January 2022)
19 slides from Moderna's conference presentation, Jan 10, 2022
Slide 1: Moderna Presentation, 40th Annual J.P. Morgan Healthcare Conference
DNA mRNA Protein Moderna Presentation 40th Annual J.P. Morgan Healthcare Conference January 10th, 2022
Slide 2: Forward-looking statements and disclaimer
Forward-looking statements and disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the Company’s efforts to continue developing vaccines against COVID-19, including ef
Slide 3: Moderna COVID-19 Vaccine: Authorized Use & Important Safety Information
Moderna COVID-19 Vaccine: Authorized Use & Important Safety Information Authorized Use in the United States: Moderna COVID-19 Vaccine is authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respira
Slide 4: 2021: A year where we had the privilege to help hundreds of millions of people
2021: A year where we had the privilege to help hundreds of millions of people ▪ 807 million doses of Moderna COVID-19 vaccine shipped around the world* ▪ ~25% of doses were shipped to middle- and low-income countries (direct sales and donations from high-income countries) ▪ Product sales of ~$17.5
Slide 5: 2021: A year where we had the privilege to help hundreds of millions of people
2021: A year where we had the privilege to help hundreds of millions of people ▪ 807 million doses of Moderna COVID-19 vaccine shipped around the world* ▪ ~25% of doses were shipped to middle- and low-income countries (direct sales and donations from high-income countries) ▪ Product sales of ~$17.5
Slide 6: Signed advanced purchase agreements and options for delivery in 2022
Moderna COVID-19 Vaccine/SpikevaxTM: Signed advanced purchase agreements (APAs) and options for delivery in 2022 3Q21 Earnings Call J.P. Morgan Conference (Nov. 4th, 2021) (Jan. 10th, 2022) Signed APAs $17B ~$18.5B Options Up to $3B ~$3.5B (probability weighted) Slide 6
Slide 7: Moderna COVID-19 Vaccine/Spikevax is only our 1st medicine to market
Moderna COVID-19 Vaccine/SpikevaxTM is only our 1st medicine to market Commercial Phase 3 Phase 2/3 Phase 2 40 development Pipeline Moderna COVID-19 Vaccine/SpikevaxTM CMV RSV Flu, COVID-19 boosters, programs Zika, PCV, VEGF-A Respiratory vaccines Latent vaccines mRNA therapeutics Programs in develo
Slide 8: Our product strategy going into 2022
Our product strategy going into 2022 1 Bring to market a pan-respiratory annual booster vaccine (which we will continuously customize) 2 Bring to market first-in-class vaccines for latent viruses 3 Bring to market therapeutics based on mRNA-encoded proteins 4 Bring to market therapeutics based on mR
Slide 9: How we think SARS-CoV-2 will evolve
How we think SARS-CoV-2 will evolve (slide from April 14, 2021 Vaccines Day) ILLUSTRATIVE Stage Focus for vaccines Pandemic Endemic • Heavy focus on protecting high-risk Pandemic populations Initial waves 2020 • Mostly ancestral virus vaccine Morbidity 2021-2022 2023+ Variant • Focus on suppressing
Slide 10: Our vision for pan-respiratory annual booster vaccines
Our vision for pan-respiratory annual booster vaccines Pan-respiratory vaccine can be customized with different viruses across season (time), demographics and geography Geography Over time: ▪ Protection against more and more viruses Age ▪ Protection against the Group circulating strains that season
Slide 11: In-country mRNA vaccine manufacturing capability to drive long-term partnerships with governments
In-country mRNA vaccine manufacturing capability to drive true long-term partnerships with governments Investments Health security Pandemic preparedness Moderna invests to bring Countries acquire portfolio Countries gain direct state-of-the-art mRNA of innovative vaccines access to rapid pandemic pl
Slide 12: Our product strategy going into 2022
Our product strategy going into 2022 1 Bring to market a pan-respiratory annual booster vaccine (which we will continuously customize) 2 Bring to market first-in-class vaccines for latent viruses: CMV, EBV, HIV and more in the labs 3 Bring to market therapeutics based on mRNA-encoded proteins 4 Brin
Slide 13: Our product strategy going into 2022
Our product strategy going into 2022 1 Bring to market a pan-respiratory annual booster vaccine (which we will continuously customize) 2 Bring to market first-in-class vaccines for latent viruses Bring to market therapeutics based on mRNA-encoded proteins: Oncology, Cardiovascular, Rare 3 diseases,
Slide 14: Our product strategy going into 2022
Our product strategy going into 2022 1 Bring to market a pan-respiratory annual booster vaccine (which we will continuously customize) 2 Bring to market first-in-class vaccines for latent viruses 3 Bring to market therapeutics based on mRNA-encoded proteins 4 Bring to market therapeutics based on mR
Slide 15: We will make progress on important expansions announced in 2021
We will make progress on important expansions announced in 2021 Announced plans to invest up to $500M in manufacturing facility in Africa Pledge to achieve net-zero carbon emissions globally by 2030 Investing in Moderna Science Center in Cambridge, MA Launched AI Academy in partnership with Carnegie
Slide 16: Moderna's capital allocation priorities
Moderna’s capital allocation priorities R&D Expense1 (in $B) Capital Expenditure (in $B) Reinvest in the business & ~2.5-3 accelerate investment in R&D, ~2 1 manufacturing infrastructure and 1.4 ~0.8 0.5 ~0.4 company buildout <0.1 0.1 2019 2020 2021E 2022E 2019 2020 2021E 2022E Seek attractive exter
Slide 17: Our mRNA platform is a unique opportunity to impact prevention and treatment of diseases
Our mRNA platform is a unique opportunity to profoundly impact prevention and treatment of diseases 1 Bring to market a pan-respiratory annual booster vaccine (which we will continuously customize) 2 Bring to market first-in-class vaccines for latent viruses 3 Bring to market therapeutics based on m
Slide 18: Our mission
Our mission To deliver on the promise of mRNA science to create a new generation of transformative medicines for patients. Slide 18
Slide 19: Thank you!
We've been at this a for ten years Our mRNA platform is a modern approach to medicine. But it’s just the beginning. Thank you! moderna
Moderna — 40th Annual J.P. Morgan Healthcare Conference (January 2022) on 6ix